

## Datasheet: MCA1271SBV790

**BATCH NUMBER 100005608**

<b>Description:</b>	MOUSE ANTI HUMAN CD33:StarBright Violet 790
<b>Specificity:</b>	CD33
<b>Format:</b>	StarBright Violet 790
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	WM53
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	100 TESTS/0.5ml

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Human		
<b>Product Form</b>	Purified IgG conjugated to StarBright Violet 790 - liquid		
<b>Max Ex/Em</b>	<b>Fluorophore</b>	<b>Excitation Max (nm)</b>	<b>Emission Max (nm)</b>
	StarBright Violet 790	401	782
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant		
<b>Buffer Solution</b>	Phosphate buffered saline		
<b>Preservative</b>	0.09% Sodium Azide (NaN <sub>3</sub> )		
<b>Stabilisers</b>	1% Bovine Serum Albumin		
	0.1% Pluronic F68		
	0.1% PEG 3350		
	0.05% Tween 20		

<b>Immunogen</b>	Human AML cells
<b>External Database Links</b>	<p><b>UniProt:</b>  <a href="#">P20138</a>    <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b>  <a href="#">945</a>    CD33    <a href="#">Related reagents</a></p>
<b>Synonyms</b>	SIGLEC3
<b>Fusion Partners</b>	Spleen cells from immunized BALB/c mice were fused with cells of the mouse NS1 myeloma cell line
<b>Specificity</b>	<p><b>Mouse anti Human CD33 antibody, clone WM53</b> recognizes the human CD33 cell surface glycoprotein. This antigen, considered to be specific for the myeloid lineage, has also been reported to be present on cells of lymphoid origin.</p> <p>Mouse anti Human CD33 antibody, clone WM53 immunoprecipitates a protein of ~75 kDa from myeloid cells, a smaller protein of approximately 67 kDa has been observed in immunoprecipitates from lymphoid targets.</p>
<b>Flow Cytometry</b>	Use 5ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
<b>References</b>	<ol style="list-style-type: none"> <li>1. Favaloro, E.J. <i>et al.</i> (1987) Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, gp67 (CD-33). <a href="#">Dis Markers. 5 (4): 215-25.</a></li> <li>2. Favaloro, E.J. <i>et al.</i> (1988) Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. <a href="#">Br J Haematol. 69 (2): 163-71.</a></li> <li>3. Hernández-Caselles, T. <i>et al.</i> (2006) A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. <a href="#">J Leukoc Biol. 79: 46-58.</a></li> <li>4. Biedermann, B. <i>et al.</i> (2006) Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. <a href="#">Leuk Res. 31: 211-20.</a></li> <li>5. Lajaunias, F. <i>et al.</i> (2005) Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. <a href="#">Eur J Immunol. 35: 243-51.</a></li> <li>6. Pietschmann, P. <i>et al.</i> (2000) Surface markers and transendothelial migration of dendritic cells from elderly subjects. <a href="#">Exp Gerontol. 35: 213-24.</a></li> <li>7. Favaloro, E.J. <i>et al.</i> (1993) Differential expression of surface antigens on activated endothelium. <a href="#">Immunol Cell Biol. 71:571-81.</a></li> <li>8. Yasukawa, T. <i>et al.</i> (2012) Simple detection of surface antigens on living cells by applying distinct cell positioning with negative dielectrophoresis. <a href="#">Anal Chem. 84 (20): 8830-6.</a></li> <li>9. Hu, Z. <i>et al.</i> (2016) Self-assembled nanoparticles based on folic acid modified</li> </ol>

carboxymethyl chitosan conjugated with targeting antibody [J Wuhan Univ of Technol-Mater. Sci. Ed. 31 \(2\): 446-53.](#)

10. Dahl C *et al.* (2004) Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured *in vitro*. [Allergy. 59 \(10\): 1087-96.](#)

11. Vamvakopoulos, J.E. & Green, C. (2003) HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. [BMC Cardiovasc Disord. 3: 6.](#)

12. Vamvakopoulos, J. *et al.* (2002) Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. [Eur J Immunol. 32 \(10\): 2988-96.](#)

13. Lin, C.W. *et al.* (2005) CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. [Blood. 106 \(10\): 3567-74.](#)

14. McCormack E *et al.* (2013) Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. [Blood. 121 \(7\): e34-42.](#)

15. Hernández-Caselles T *et al.* (2019) CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway. [J Immunol Res. 2019: 6032141.](#)

---

<b>Storage</b>	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA1271SBV790">https://www.bio-rad-antibodies.com/SDS/MCA1271SBV790</a> 20471
<b>Regulatory</b>	For research purposes only

---

## Related Products

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M387261:210621'

Printed on 14 Mar 2023